• Je něco špatně v tomto záznamu ?

Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice

B. Sak, K. Brdíčková, N. Holubová, D. Květoňová, L. Hlásková, M. Kváč

. 2020 ; 64 (5) : . [pub] 20200421

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020630
E-zdroje Online Plný text

NLK Free Medical Journals od 1972 do Před 6 měsíci
Freely Accessible Science Journals od 1995 do Před 6 měsíci
PubMed Central od 1972 do Před 1 rokem
Europe PubMed Central od 1972 do Před 6 měsíci
Open Access Digital Library od 1972-01-01
Open Access Digital Library od 1972-01-01

Odkazy

PubMed 32152088
DOI 10.1128/aac.00058-20
Knihovny.cz E-zdroje

Of four genotypes of Encephalitozoon cuniculi, E. cuniculi genotype II is considered to represent a parasite that occurs in many host species in a latent asymptomatic form, whereas E. cuniculi genotype III seems to be more aggressive, and infections caused by this strain can lead to the death of even immunocompetent hosts. Although albendazole has been considered suitable for treatment of Encephalitozoon species, its failure in control of E. cuniculi genotype III infection has been reported. This study determined the effect of a 100× recommended daily dose of albendazole on an Encephalitozoon cuniculi genotype III course of infection in immunocompetent and immunodeficient mice and compared the results with those from experiments performed with a lower dose of albendazole and E. cuniculi genotype II. The administration of the regular dose of abendazole during the acute phase of infection reduced the number of affected organs in all strains of mice and absolute counts of spores in screened organs. However, the effect on genotype III was minor. Surprisingly, no substantial effect was recorded after the use of a 100× dose of albendazole, with larger reductions seen only in the number of affected organs and absolute counts of spores in all strains of mice, implying variations in albendazole resistance between these Encephalitozoon cuniculi genotypes. These results imply that differences in the course of infection and the response to treatment depend not only on the immunological status of the host but also on the genotype causing the infection. Understanding how microsporidia survive in hosts despite targeted antimicrosporidial treatment could significantly contribute to research related to human health.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020630
003      
CZ-PrNML
005      
20210830102243.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1128/AAC.00058-20 $2 doi
035    __
$a (PubMed)32152088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sak, Bohumil $u Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic casio@paru.cas.cz
245    10
$a Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice / $c B. Sak, K. Brdíčková, N. Holubová, D. Květoňová, L. Hlásková, M. Kváč
520    9_
$a Of four genotypes of Encephalitozoon cuniculi, E. cuniculi genotype II is considered to represent a parasite that occurs in many host species in a latent asymptomatic form, whereas E. cuniculi genotype III seems to be more aggressive, and infections caused by this strain can lead to the death of even immunocompetent hosts. Although albendazole has been considered suitable for treatment of Encephalitozoon species, its failure in control of E. cuniculi genotype III infection has been reported. This study determined the effect of a 100× recommended daily dose of albendazole on an Encephalitozoon cuniculi genotype III course of infection in immunocompetent and immunodeficient mice and compared the results with those from experiments performed with a lower dose of albendazole and E. cuniculi genotype II. The administration of the regular dose of abendazole during the acute phase of infection reduced the number of affected organs in all strains of mice and absolute counts of spores in screened organs. However, the effect on genotype III was minor. Surprisingly, no substantial effect was recorded after the use of a 100× dose of albendazole, with larger reductions seen only in the number of affected organs and absolute counts of spores in all strains of mice, implying variations in albendazole resistance between these Encephalitozoon cuniculi genotypes. These results imply that differences in the course of infection and the response to treatment depend not only on the immunological status of the host but also on the genotype causing the infection. Understanding how microsporidia survive in hosts despite targeted antimicrosporidial treatment could significantly contribute to research related to human health.
650    _2
$a albendazol $x aplikace a dávkování $x farmakologie $7 D015766
650    _2
$a zvířata $7 D000818
650    _2
$a antifungální látky $x aplikace a dávkování $x farmakologie $7 D000935
650    _2
$a antigeny CD4 $x genetika $7 D015704
650    _2
$a antigeny CD8 $x genetika $7 D016827
650    _2
$a buněčné linie $7 D002460
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a počet mikrobiálních kolonií $7 D015169
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a Encephalitozoon cuniculi $x účinky léků $x genetika $x izolace a purifikace $7 D009670
650    _2
$a encephalitozoonóza $x farmakoterapie $7 D016890
650    _2
$a genotyp $7 D005838
650    _2
$a imunokompromitovaný pacient $x imunologie $7 D016867
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a myši SCID $7 D016513
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a Vero buňky $7 D014709
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brdíčková, Klára $u Faculty of Science, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic
700    1_
$a Holubová, Nikola $u Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic $u Faculty of Agriculture, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic
700    1_
$a Květoňová, Dana $u Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic
700    1_
$a Hlásková, Lenka $u Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic
700    1_
$a Kváč, Martin $u Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic $u Faculty of Agriculture, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic
773    0_
$w MED00009215 $t Antimicrobial agents and chemotherapy $x 1098-6596 $g Roč. 64, č. 5 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32152088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102244 $b ABA008
999    __
$a ok $b bmc $g 1691245 $s 1141076
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 64 $c 5 $e 20200421 $i 1098-6596 $m Antimicrobial agents and chemotherapy $n Antimicrob Agents Chemother $x MED00009215
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace